Clear Street raised BioNTech’s price target to $185 from $181, maintaining a Buy rating. Phase 2 results for BNT327 in lung and breast cancer expected in second half of 2025. Analyst praises company’s oncology pipeline. Unlock TipRanks Premium for investing tools and expert insights. Stay updated with real-time financial news on TheFly.

Read more at Yahoo Finance: BioNTech price target raised to $185 from $181 at Clear Street